The $550 million convertible senior notes offering was upsized from a previously announced offering of $350 million.

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its ...

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

After a heart attack, the heart struggles to recoup and maintain energy. One third of patients develop heart failure as a ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a result—a condition that impacts 6.8 million Americans and carries a high ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution.

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

The MarketWatch News Department was not involved in the creation of this content. New Toolkit Allows Researchers to Test Potential Cancer Targets Directly in Patient-Leukemia Cells PHILADELPHIA, Feb.

ARK Invest deployed over $10M in CRISPR Therapeutics and PayPay Corp on March 12, while cutting positions in Teradyne and Ionis Pharmaceuticals.

Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first ...

CRISPR Therapeutics (CRSP) upsized a $550M convertible notes deal due 2031 at 1.125%, with a 45% conversion premium—get the key terms now.

PHILADELPHIA, Feb. 26, 2026 /PRNewswire/ -- A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an ...